IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc. IMBRUVICA (ibrutinib) is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton’s tyrosine
The strategic alliance includes the granting of manufacturing rights by ProMetic to GENERIUM for several plasma-derived biopharmaceuticals using ProMetic’s proprietary PPPS technology. In addition, ProMetic will provide training
"RAPIVAB is the first neuraminidase inhibitor that has shown to be safe and effective as a single-dose, i.v. therapy for patients with acute, uncomplicated influenza, and represents the
NewLink Genetics’ wholly-owned subsidiary, BioProtection Systems, is the prime contractor in a $30 million contract to support the manufacturing and development activities of its investigational rVSV-EBOV (Ebola) vaccine
The partner has received an exclusive option to obtain U.S. commercial rights to SST’s topical ibuprofen (SST-0225) upon its approval by the U.S. FDA. SST-0225 is a patented
Sibutramine is an appetite suppressant that was withdrawn from the U.S. market in October 2010 (due to increased risk of seizures, heart attacks, arrhythmia and strokes). Phenolphthalein is
Nuvilex’s pancreatic cancer treatment combines Nuvilex’s patented and proprietary cellulose-based encapsulation technology, known as Cell-in-a-Box(R), with the cancer prodrug ifosfamide and encapsulated live cells that convert the prodrug
Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, commented, "The submission of an IND for NS2 in the treatment of noninfectious anterior uveitis is a major
The collaborators will use Enumeral’s human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to
OPuS-2 is a 12-week, three-arm, parallel cohort design trial to evaluate the efficacy and safety of two doses of BCX4161, 300 mg and 500 mg, administered three-times daily
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.